Antengene Corporation Ltd
HKEX:6996

Watchlist Manager
Antengene Corporation Ltd Logo
Antengene Corporation Ltd
HKEX:6996
Watchlist
Price: 3.25 HKD -7.67% Market Closed
Market Cap: 2.2B HKD

Antengene Corporation Ltd
Other Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Antengene Corporation Ltd
Other Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
Antengene Corporation Ltd
HKEX:6996
Other Liabilities
ÂĄ121.9m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Other Liabilities
ÂĄ21.5m
CAGR 3-Years
-2%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Other Liabilities
ÂĄ98.3m
CAGR 3-Years
5%
CAGR 5-Years
16%
CAGR 10-Years
15%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Other Liabilities
ÂĄ42.6m
CAGR 3-Years
-29%
CAGR 5-Years
-17%
CAGR 10-Years
N/A
Yunnan Baiyao Group Co Ltd
SZSE:000538
Other Liabilities
ÂĄ905.5m
CAGR 3-Years
1%
CAGR 5-Years
0%
CAGR 10-Years
17%
C
CSPC Innovation Pharmaceutical Co Ltd
SZSE:300765
Other Liabilities
ÂĄ94.4m
CAGR 3-Years
44%
CAGR 5-Years
21%
CAGR 10-Years
N/A

Antengene Corporation Ltd
Glance View

Market Cap
2.2B HKD
Industry
Pharmaceuticals

Antengene Corp. Ltd. operates as clinical-stage Asia-Pacific biopharmaceutical company. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2020-11-20. The firm is principally engaged in the discovery, development, manufacturing and commercialization of biotech products. The Company’s products include ATG-010 (selinexor), treating for relapsed/refractory multiple myeloma, relapsed/refractory diffuse large B-cell lymphoma and non-small cell lung cancer and ATG-008 (onatasertib), treating for hepatocellular carcinoma and non-small cell lung cancer. The firm mainly conducts its business in Asia-Pacific.

Intrinsic Value
0.42 HKD
Overvaluation 87%
Intrinsic Value
Price

See Also

What is Antengene Corporation Ltd's Other Liabilities?
Other Liabilities
121.9m CNY

Based on the financial report for Dec 31, 2024, Antengene Corporation Ltd's Other Liabilities amounts to 121.9m CNY.

What is Antengene Corporation Ltd's Other Liabilities growth rate?
Other Liabilities CAGR 1Y
41%

Over the last year, the Other Liabilities growth was 41%.

Back to Top